Cisplatin

**Section:** 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

### Indication
Malignant neoplasms of lip, oral cavity or pharynx

**INN**
Cisplatin

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

**EML status history**
First added in 1984 (TRS 722)
Changed in 2015 (TRS 994)
Changed in 2021 (TRS 1035)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions
Read more about patents.

### Tags
- Cancer

**Wikipedia**
Cisplatin

**DrugBank**
Cisplatin

### Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the addition of new strength formulations of cisplatin IV injection (10 mg/10 mL and 20 mg/20 mL) to the EML.